← Back to Search

Sun-Safe Habits Education for Skin Cancer Prevention in Adolescents (SHINE Trial)

Phase 3
Recruiting
Led By Yelena Wu, PhD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Must not have
Students will be excluded from participation if they do not speak English.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (wk 0), post-intervention (32-36 wks), follow-up 1 (36-40 wks), follow-up 2 (44-52 wks), follow-up 3 (84-88 wks)
Awards & highlights

Summary

This trial is testing whether the SHINE intervention can help high school students better protect themselves from the sun and avoid tanning.

Who is the study for?
This trial is for high school students in Utah, grades 9-12. It's designed to test if a program called SHINE can help them use sun protection and avoid intentional tanning. Students who don't speak English or have developmental delays that prevent participation are not eligible.Check my eligibility
What is being tested?
The SHINE intervention involves two in-class sessions aimed at improving sun-safe habits among adolescents. The study will compare the results of schools receiving SHINE with those getting standard education on skin cancer prevention.See study design
What are the potential side effects?
Since this trial focuses on education and behavior change rather than medication, there are no direct medical side effects expected from participating in the SHINE intervention.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I speak English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (wk 0), post-intervention (32-36 wks), follow-up 1 (36-40 wks), follow-up 2 (44-52 wks), follow-up 3 (84-88 wks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (wk 0), post-intervention (32-36 wks), follow-up 1 (36-40 wks), follow-up 2 (44-52 wks), follow-up 3 (84-88 wks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Tanning Behaviors Assessed Via Youth Risk Behavioral Surveillance System
Long Pants/Skirt Behavior Changes Assessed Via Sun Habits Survey
Long Sleeved Shirt Behavior Changes Assessed Via Sun Habits Survey
+6 more
Secondary outcome measures
Change in Sunburn Occurrence Assessed Via Sun Habits Survey
Change in Ultraviolet Radiation (UVR) Exposure Assessed Via UVR Monitor

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SHINEExperimental Treatment1 Intervention
Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
Group II: Standard EducationActive Control1 Intervention
Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,949,151 Total Patients Enrolled
University of UtahLead Sponsor
1,110 Previous Clinical Trials
1,778,306 Total Patients Enrolled
Yelena Wu, PhDPrincipal Investigator - University of Utah
Beaver Valley Hospital
University Of Utah School Of Medicine (Medical School)
University Of Ut Medical Center (Residency)
5 Previous Clinical Trials
21,364 Total Patients Enrolled

Media Library

SHINE Intervention Clinical Trial Eligibility Overview. Trial Name: NCT04341064 — Phase 3
Skin Cancer Research Study Groups: SHINE, Standard Education
Skin Cancer Clinical Trial 2023: SHINE Intervention Highlights & Side Effects. Trial Name: NCT04341064 — Phase 3
SHINE Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04341064 — Phase 3
~1354 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top